Back to Search
Start Over
Evocalcet in the management of secondary hyperparathyroidism in dialysis patients.
- Source :
-
Kidney international [Kidney Int] 2018 Oct; Vol. 94 (4), pp. 661-662. - Publication Year :
- 2018
-
Abstract
- Use of calcimimetics will be influenced not only by assessment of benefits and harms in individual patients but also by cost and by national guidelines. The Japanese Society for Dialysis Therapy has a lower PTH threshold for PTH control than other countries. The current RCT, despite its limitations, provides a rationale for use of evocalcet in the management of secondary hyperPTH.<br /> (Copyright © 2018. Published by Elsevier Inc.)
- Subjects :
- Calcimimetic Agents
Humans
Renal Dialysis
Cinacalcet
Hyperparathyroidism, Secondary
Subjects
Details
- Language :
- English
- ISSN :
- 1523-1755
- Volume :
- 94
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Kidney international
- Publication Type :
- Academic Journal
- Accession number :
- 30243312
- Full Text :
- https://doi.org/10.1016/j.kint.2018.06.022